Detalhe da pesquisa
1.
Phase 1, open-label, dose-escalation study on the safety, pharmacokinetics, and preliminary efficacy of intravenous Coxsackievirus A21 (V937), with or without pembrolizumab, in patients with advanced solid tumors.
J Immunother Cancer
; 11(1)2023 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36669791